Incyte And Astrazeneca To Enter Clinical Trial Collaboration In Early Lung Cancer

Incyte Corporation (Nasdaq:INCY) and MedImmune, AstraZeneca’s (NYSE:AZN) global biologics research and development arm, today announced the expansion of their clinical collaboration. As part of the agreement, the companies will evaluate the efficacy and safety of epacadostat, Incyte’s investigational selective IDO1 enzyme inhibitor, in combination with AstraZeneca’s Imfinzi® (durvalumab), a human monoclonal antibody directed against PD-L1, compared to Imfinzi alone.

Details:
businesswire.com/news/home/20171031005394/en/Incyte-AstraZeneca-Enter-Clinical-Trial-Collaboration-Early